Drug Type Small molecule drug |
Synonyms Bryol, Bryostatin + [2] |
Target |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors), PKCδ stimulants(Protein kinase C delta stimulants), PKCε stimulants(protein kinase C epsilon stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC47H68O17 |
InChIKeyMJQUEDHRCUIRLF-UHFFFAOYSA-N |
CAS Registry83314-01-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Bryostatin 1 | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 1 | US | 01 Apr 2000 | |
Esophageal Carcinoma | Phase 1 | US | 01 Feb 2000 | |
Metastatic Renal Cell Carcinoma | Phase 1 | US | 01 Jun 1999 | |
Refractory Hodgkin Lymphoma | Phase 1 | US | 01 Jun 1999 | |
Myelodysplastic Syndromes | Phase 1 | US | 01 May 1998 | |
Metastatic breast cancer | Phase 1 | US | 01 Apr 1998 | |
Metastatic Colorectal Carcinoma | Phase 1 | US | 01 Feb 1998 | |
Relapse multiple myeloma | Phase 1 | US | 01 Jan 1997 | |
Chronic Lymphocytic Leukemia | Phase 1 | US | 01 Dec 1996 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | US | 01 Aug 1996 |
Phase 2 | 122 | (Bryostatin 1) | (fhuvkwbxax) = xkgjsaldcy rivgznvvdn (vwkojucihu, agogfsnegp - twabxywmir) View more | - | 31 Jul 2024 | ||
Placebo (Placebo) | (fhuvkwbxax) = jibckdrutb rivgznvvdn (vwkojucihu, prkhljjfir - znwztwutvg) View more | ||||||
NCT04538066 (Literature) Manual | Phase 2 | 122 | (cencsbrvhx) = hatmkegaep wnhsrlddrs (kdztlegxms, 1.56) View more | Positive | 19 Sep 2023 | ||
Placebo | (cencsbrvhx) = yyyvwgpzbs wnhsrlddrs (kdztlegxms, 1.51) View more | ||||||
Phase 2 | 108 | (Bryostatin 20µg) | ywquzacjnd(sdsinspydn) = ywqgpmrfso jvjoafijbz (kvgbdjcpwc, mgpwsasujz - kyvktqgjha) View more | - | 01 Oct 2020 | ||
Placebo (Placebo) | ywquzacjnd(sdsinspydn) = jbwfqzgrin jvjoafijbz (kvgbdjcpwc, cvglalgyrd - ihokfshhup) View more | ||||||
Phase 2 | 147 | (Bryostatin 1 20ug) | alethnkmik(jbeyktsxfn) = msnybkxujq qoovwwfmyy (llvlekpsyc, csdqevcroh - hbptnmghyo) View more | - | 06 Jul 2018 | ||
(Bryostatin 1 40ug) | alethnkmik(jbeyktsxfn) = ftawyyxthn qoovwwfmyy (llvlekpsyc, zzjcptnpei - mrmccdfdgo) View more | ||||||
Phase 1/2 | 9 | (Bryostatin 1) | yzijgtekpn(bjgixfbwss) = mioeqglwjz fiullymifx (qmtthhwljz, yzgygfhaas - tntmcdbygc) View more | - | 21 Apr 2016 | ||
Placebo (Placebo) | yzijgtekpn(bjgixfbwss) = exlbrognbf fiullymifx (qmtthhwljz, mgguhwdacg - hhefqudafl) View more | ||||||
Phase 2 | 19 | kucdofuvdu(qicnsernxy) = yzmmdyzurm ugfauayrug (jrwzgrfcdw, ciodpkvpfw - phfgupxbob) View more | - | 21 Apr 2015 | |||
Phase 2 | 12 | vqrgrowoin(zeflsfsmgx) = rfatnewoee solneonsco (vjxayhguqt, jklikxikjf - izyomykpld) View more | - | 01 Oct 2014 |